Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis

<p>Abstract</p> <p>Background</p> <p>Single drug use has not achieved satisfactory results in the treatment of prostate cancer, despite application of increasingly widespread targeted therapeutics. In the present study, the combined impact of the mammalian target of rapamycin (mTOR)-inhibitor RAD001...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Waaga-Gasser Ana, Tsaur Igor, Juengel Eva, Makarević Jasmina, Seibel Jens-Michael, Hudak Lukasz, Wedel Steffen, Haferkamp Axel, Blaheta Roman A
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2011-08-01
coleção:	BMC Cancer
Acesso em linha:	http://www.biomedcentral.com/1471-2407/11/375
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!